This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PYGM / Glycogen phosphorylase, muscle form · IHC design guide
Design Immunohistochemistry for PYGM
Plan PYGM staining in paraffin sections around the cytoplasmic signal observed in skeletal myocytes (HPA tissue IHC). This guide covers fixation consistency, antibody use and interpretation of chromogenic staining.
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PYGM Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic staining in skeletal myocytes (HPA tissue IHC) | |
| Staining pattern | Strong staining in skeletal myocyte cytoplasm (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02971-1) | |
| Positive control | Skeletal muscle | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Myocyte content can change the apparent tissue signal (HPA tissue IHC) | |
| Regulation | Abundance regulation unreported (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended PYGM IHC & IF Protocols
The catalog antibody has an IHC-P protocol (datasheet A02971-1). Published PYGM IHC methods below provide osteosarcoma staining conditions and a cattle-study detection system (PMC13219957; PMC11055281).
| Sample | Paraffin-embedded human bladder cancer tissue; fixative not specified (datasheet A02971-1) |
| Fixation | Image fixative and duration unreported (datasheet A02971-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02971-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02971-1) |
| Primary antibody | Rabbit anti-PYGM, 2-5 μg/ml (datasheet A02971-1) |
| Primary incubation | Overnight at 4 °C (datasheet A02971-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A02971-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PYGM-positive staining in myocytes of skeletal muscle (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in skeletal muscle. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA, pH 8.0 (datasheet A02971-1). Citrate, pH 6.0, under high pressure is a published alternative (PMC13219957).
Section 2
What Is the Expected PYGM Staining Pattern?
PYGM should appear in the cytoplasm of skeletal muscle myocytes, with high staining in the supplied tissue IHC profile (HPA: High in skeletal muscle myocytes; cytoplasmic expression). The tissue result has Enhanced reliability, reflecting agreement between antibody staining and RNA expression (HPA: Enhanced). PYGM has no annotated transmembrane segment; UniProt provides no subcellular location annotation (UniProt P11217 topology and subcellular record).
| Strong cytoplasmic chromogen in skeletal muscle myocytes, with recognizable cell boundaries. | This matches the expected positive pattern (HPA: High in skeletal muscle myocytes; cytoplasmic expression). Judge localization within myocytes, alongside the distribution of staining, before treating intensity alone as evidence of PYGM. |
| A dominant nuclear, sharply membranous, or extracellular deposit replaces the cytoplasmic pattern. | Treat this as discordant with the observed tissue pattern (HPA: cytoplasmic expression). Review morphology, counterstain, retrieval, and detection controls before assigning a biological location; UniProt does not supply an independent subcellular annotation (UniProt P11217 subcellular record). |
| Strong signal appears in adipocytes or respiratory epithelial cells. | These cells were reported as not detected in the supplied tissue profile (HPA: adipocytes and bronchial respiratory epithelial cells, Not detected). Investigate cross-reactivity or endogenous detection activity; a positive deposit in a negative-reference cell does not establish PYGM expression. |
| Weak, widespread chromogen covers cells and surrounding section without a clear cytoplasmic boundary. | This is background until controls show a cell-specific pattern (general IHC practice). Compare a reagent control and the known-positive skeletal muscle area; the reference pattern is cytoplasmic myocyte staining (HPA: skeletal muscle tissue IHC). |
| No signal is visible in skeletal muscle myocytes. | The known-positive reference has high myocyte staining (HPA: High in skeletal muscle myocytes). First verify tissue identity and staining-run controls, then review the catalog antibody's IHC-P instructions; an isolated negative slide cannot establish absent PYGM. |
💡Expected PYGM appearanceCall positive when skeletal muscle myocytes show high cytoplasmic staining (HPA: skeletal muscle tissue IHC); dominant nuclear, membranous, or negative-reference cell staining warrants investigation rather than a PYGM-positive call (HPA: cytoplasmic profile; specified Not detected cells).
| Reference tissue and cell type | Skeletal muscle myocytes provide the supplied high-staining reference; adipocytes and bronchial respiratory epithelial cells are listed as not detected (HPA: tissue IHC). Keep those cell identities explicit when judging a section. |
| Evidence strength | The tissue result is Enhanced, with high consistency between antibody staining and RNA expression (HPA: reliability description). One listed antibody has Enhanced IHC validation (HPA: HPA056003); this supports the reported pattern, not every possible staining condition. |
| Topology and location | PYGM has no annotated transmembrane segment (UniProt P11217 topology), while its subcellular location is unannotated (UniProt P11217 subcellular record). Use the observed HPA cytoplasmic IHC pattern for the slide decision. |
| Isoforms and processing | Two isoforms are listed, and the annotated protein chain spans residues 2–842 (UniProt P11217 isoforms and processing). No epitope location is supplied, so this record cannot predict isoform-specific staining or an antigen retrieval requirement. |
| Can ICC-IF confirm the compartment? | The supplied HPA ICC-IF record gives no main location and lists no imaged cell lines (HPA: subcellular record). It adds no independent localization check here; consult the separate IF/ICC guide for that application. |
| Situation | Likely cause | Next action |
|---|---|---|
| Skeletal muscle myocytes are unstained. | A failed or unsuitable staining run is possible; the supplied reference expects high myocyte staining (HPA: skeletal muscle tissue IHC). | Confirm tissue identity and positive-control performance, then check retrieval, antibody dilution, and detection against the catalog antibody's IHC-P instructions (general IHC practice). |
| Nuclei dominate the signal. | The compartment conflicts with the reported cytoplasmic pattern (HPA: tissue IHC). The image alone cannot distinguish nonspecific binding from a detection artefact. | Check the counterstain and reagent control, then reassess staining at cell-level magnification before scoring PYGM (general IHC practice). |
| Adipocytes stain strongly. | Adipocytes are reported as not detected in the supplied tissue profile (HPA: adipose tissue and breast adipocytes). Cross-reactivity or endogenous detection activity is possible. | Compare the suspect cells with a negative-reference section and the reagent control; review blocking and detection steps (general IHC practice). |
| Chromogen is diffuse across the section. | A diffuse deposit lacks the cell-specific cytoplasmic pattern reported for PYGM (HPA: skeletal muscle tissue IHC). Background may arise during the staining workflow (general IHC practice). | Inspect the reagent control and compare localized myocyte signal with the surrounding section; review blocking, washes, and detection (general IHC practice). |
| Only a membranous rim appears around myocytes. | A dominant membrane pattern disagrees with the HPA cytoplasmic observation (HPA: tissue IHC); no transmembrane segment is annotated (UniProt P11217 topology). | Check whether chromogen also occupies the cytoplasm and whether the same rim appears in controls before accepting the stain (general IHC practice). |
| One section stains more weakly than another. | The supplied sources do not establish a PYGM-specific fixation or retrieval effect (HPA: tissue IHC; UniProt P11217 record). Tissue identity and run conditions need comparison. | Compare myocyte preservation, control staining, retrieval, dilution, and detection records for the two runs (general IHC practice); avoid assigning a PYGM-specific cause without evidence. |
Experiment evidence
IHC & IF images showing PYGM staining
A02971-1 · IHCIHC analysis of PYGM using anti-PYGM antibody (A02971-1). PYGM was detected in a paraffin-embedded section of human bladder cancer tissue. H
A02971-1 · IHCIHC analysis of PYGM using anti-PYGM antibody (A02971-1). PYGM was detected in a paraffin-embedded section of human lung cancer tissue. Heat
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000068976-PYGM/tissue/cerebral+cortex#imid_15756947
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000068976-PYGM/tissue/colon#imid_15755713
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000068976-PYGM/tissue/liver#imid_15755730
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000068976-PYGM/tissue/kidney#imid_15755731
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PYGM IHC & IF
🧪Run skeletal muscle first; myocytes should stain strongly (HPA: High in skeletal-muscle myocytes). Use adipose tissue as the negative comparator (HPA: Not detected in adipocytes); on the muscle slide, morphologically identified non-myocytes should show background-level signal to serve as internal negative candidates, but their PYGM status requires validation (HPA: reports High in myocytes only).
Positive control tissue: Skeletal muscle (Myocytes, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for PYGM; derive a cell-line control from the positive tissue's cell type (Myocytes) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control, a rabbit IgG isotype control matched to the primary antibody’s clonality where known, and PYGM-knockout material or cognate-peptide competition where available (selected-SKU caption: rabbit primary; standard IHC control practice). For chromogenic detection, quench endogenous peroxidase and block endogenous biotin if using avidin–biotin detection; for IF, assess skeletal-muscle autofluorescence (standard IHC/IF practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected-SKU paraffin-section caption does not state a fixative (selected-SKU tissue-IHC caption). That caption uses heat-mediated EDTA retrieval at pH 8.0, but it does not establish that retrieval is required for every specimen (selected-SKU tissue-IHC caption). The supplied evidence does not establish that frozen sections or IF are easier than IHC-P; skeletal-muscle autofluorescence should be checked if IF is attempted (HPA: no ICC-IF images listed; selected-SKU caption: paraffin-section IHC; standard IF practice).
HPA tissue IHC evidence for PYGM
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Skeletal muscle | Myocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Endocrine cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced PYGM IHC Tips
Troubleshoot PYGM staining in paraffin sections by checking retrieval, tissue controls, cytoplasmic localisation and the limits of the selected antibody’s evidence.
How should I retrieve PYGM when staining is weak?
Use heat-mediated retrieval in EDTA at pH 8.0 for PYGM paraffin IHC (datasheet A02971-1). The selected tissue image used this retrieval before overnight primary-antibody incubation at 4°C, so reproduce those conditions as the starting point (caption A02971-1). If staining remains weak, adjust heating duration in small increments while keeping a skeletal-muscle control beside the test section; compare signal and tissue integrity after each change (HPA: high in skeletal-muscle myocytes; standard IHC practice). If an alternative buffer is tested, treat it as a fallback and score it against the EDTA condition using matched sections and detection settings (standard IHC practice).
Could fixation explain inconsistent PYGM staining across sections?
PYGM-specific sensitivity to fixation is unknown from the supplied evidence, and the selected image identifies a paraffin section without stating its fixative (caption A02971-1). Record the fixative, fixation time and section age for each specimen before attributing a weak result to antigen loss (standard IHC practice). Process a skeletal-muscle control alongside test sections, then compare staining after the same EDTA pH 8.0 retrieval and 2 μg/ml primary-antibody incubation (HPA: high in skeletal-muscle myocytes; caption A02971-1). If signal differs between batches, change one processing variable at a time and inspect morphology as well as DAB intensity (standard IHC practice).
Where should convincing PYGM signal appear in tissue?
Look for cytoplasmic staining in skeletal-muscle myocytes, the positive tissue and cell type identified by tissue IHC (HPA: cytoplasmic expression in skeletal muscle; HPA: high in myocytes). PYGM has no annotated transmembrane segment, but its UniProt subcellular location is unannotated; use the observed IHC pattern to guide scoring rather than assigning a finer compartment (UniProt P11217; HPA tissue IHC). Compare candidate staining with a skeletal-muscle control and with adipocytes, where protein was not detected (HPA tissue IHC). Isolated nuclear outlines or surface-only DAB deposits warrant a review of counterstain, section folds and detection background before being scored as PYGM (standard IHC practice).
Can this stain distinguish PYGM isoforms or phosphorylation states?
Do not interpret the catalog antibody’s chromogenic signal as isoform-specific: the record lists 2 PYGM isoforms, while the supplied caption gives no antibody epitope or isoform validation (UniProt P11217; caption A02971-1). The record also lists phosphorylation at residue 15 and other modified residues, but no evidence links this antibody’s staining to a particular modification (UniProt P11217; caption A02971-1). If that distinction matters, obtain epitope and cross-reactivity documentation and compare appropriately characterised controls before assigning a molecular state (standard IHC practice). Report the result as PYGM immunoreactivity, with the scored cell type and cytoplasmic pattern, unless that additional validation supports a narrower claim (HPA tissue IHC; standard IHC practice).
How can I adapt the PYGM question to multiplex IF?
For the separate IF/ICC workflow, pair PYGM with a marker that identifies skeletal-muscle myocytes, the expected positive cell type in tissue IHC (HPA: high in skeletal-muscle myocytes). Choose a fluorophore channel with low tissue autofluorescence and examine an unstained section in every channel before interpreting colocalisation (standard IF practice). PYGM has no annotated transmembrane segment, but the antibody epitope is unreported; verify intracellular access with a mild permeabilisation comparison instead of assuming which membrane side the epitope occupies (UniProt P11217; caption A02971-1; standard IF practice). The supplied product image documents paraffin chromogenic IHC, so establish IF specificity with appropriate controls before transferring its staining interpretation (caption A02971-1; standard IF practice).
What should I check when PYGM DAB staining looks diffuse?
Check the no-primary control for detection background, and inspect section edges, folds and damaged areas before changing antibody concentration (standard IHC practice). The selected image used 10% goat-serum blocking, 2 μg/ml primary antibody overnight at 4°C, and a peroxidase-linked secondary before DAB development (caption A02971-1). Include a peroxidase block as a general chromogenic IHC step, then compare matched sections developed for the same time (standard IHC practice). A convincing result should remain cell-associated and cytoplasmic in the positive skeletal-muscle control; widespread staining in adipocytes would prompt a background check (HPA tissue IHC; standard IHC practice).
How should I quantify PYGM staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and viable tissue area before scoring, using skeletal-muscle myocytes as the documented positive reference (HPA tissue IHC; standard IHC practice). For cell-based scoring, record the percentage of positive myocytes and staining intensity, or calculate an H-score from 0–300 using consistent intensity categories (standard IHC practice). For spatial comparisons, report positive-cell density per mm² of viable tissue and normalise to myocyte number or myocyte-containing area when composition varies (standard IHC practice). Keep retrieval, DAB development and image thresholds matched, and exclude folds, edges and necrotic regions before comparing specimens (caption A02971-1; standard IHC practice).
How can I separate true PYGM staining from artefact?
Prioritise reproducible cytoplasmic signal in skeletal-muscle myocytes over isolated DAB deposits, because that cell type and pattern have tissue-IHC support (HPA tissue IHC). Staining confined to nuclei, section edges or necrotic regions requires inspection against morphology and controls before interpretation (standard IHC practice). PYGM lacks an annotated transmembrane segment, so a membrane-only pattern needs independent validation before it is assigned to this target (UniProt P11217; standard IHC practice). Check a no-primary control and peroxidase block for endogenous enzyme or detection signal, and compare adipocytes, where PYGM protein was not detected, without treating a negative cell type as a substitute for antibody-specificity validation (HPA tissue IHC; standard IHC practice).
Boster reagents
Best PYGM / Glycogen phosphorylase, muscle form IHC Antibodies
A02971-1 has IHC images from human bladder, lung, liver and colon cancer paraffin sections (catalog image captions). Reactivity includes human, mouse and rat (catalog: A02971-1).
Real IHC data
Anti-PYGM Antibody ®
Cat # A02971-1
A02971-1 is listed for IHC in human, mouse and rat samples (catalog: A02971-1). Its images show staining in human bladder, lung, liver and colon cancer paraffin sections (catalog image captions: A02971-1).
Which to pick: Choose A02971-1 for paraffin-section IHC: its caption reports EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody, while the catalog lists an IHC range of 2–5 μg/ml (image caption and catalog: A02971-1); the fixative is unreported (image caption: A02971-1). For IF/ICC, this payload provides no listed application, dilution or image, so it does not establish an IF/ICC choice (catalog: A02971-1). For cross-species IHC, A02971-1 lists human, mouse and rat reactivity, though the supplied IHC images show human tissue only (catalog and image captions: A02971-1).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P11217 (PYGM_HUMAN, Glycogen phosphorylase, muscle form).
- Human Protein Atlas. PYGM tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. PYGM subcellular location (ICC-IF): Highest expression in Rh30: 1.9 nTPM.
- Human Protein Atlas. PYGM antibody validation summary (1 antibodies).
- Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease. Cells 2021 — PMC8070155.
- Machine Learning-Based Identification and Validation of PYCR1 and PYGM as Prognostic Biomarkers for Osteosarcoma. Clinical Medicine Insights. Oncology 2026 — PMC13219957.
- Proteomic dissection of vanishing white matter pathogenesis. Cellular and molecular life sciences : CMLS 2024 — PMC11126554.
- An autosomal recessive variant in PYGM causes myophosphorylase deficiency in Red Angus composite cattle. BMC genomics 2024 — PMC11055281.
- PubMed PMID:3447177 — UniProt-cited evidence.
- PubMed PMID:9633816 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PYGM (Glycogen phosphorylase, muscle form). Expected localisation Cytoplasmic staining in skeletal myocytes (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02971-1). Validated IHC antibody: A02971-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Skeletal muscle (Myocytes); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human bladder cancer tissue; fixative not specified (datasheet A02971-1); 2. Fixation: Image fixative and duration unreported (datasheet A02971-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02971-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02971-1); 8. Primary antibody: Rabbit anti-PYGM, 2-5 μg/ml (datasheet A02971-1); 9. Primary incubation: Overnight at 4 °C (datasheet A02971-1). Watch for: Fixation: Keep fixation conditions consistent across sections (standard IHC practice; not target-specific); Caveat: Myocyte content can change the apparent tissue signal (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage is unspecified (UniProt); Regulation: Abundance regulation unreported (UniProt). Evidence: UniProt P11217, HPA tissue IHC · Enhanced, HPA cell-line RNA · Highest expression in Rh30: 1.9 nTPM, Datasheet A02971-1, PMC13219957, PMC11055281. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PYGM/immunohistochemistry-ihc-guide.